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REKABENTUK DRUG BERBANTU KOMPUTER UNTUK PERENCAT
NEURAMINIDASE YANG BERPOTENSI DARI EKSTRAK TUMBUHAN
ABSTRAK
Neuraminidase (NA) dari virus influenza bertanggungjawab dalam proliferasi dan
jangkitan virus, menyebabkan beberapa usaha untuk menemui dan mengoptimumkan
perencat baru neuraminidase digiatkan. Tujuan kajian ini adalah untuk menemukan
perencat baru NA melalui penggabungan kaedah berbantu komputer (model
farmakofor dan pendokkan molekular) dan kaedah pemencilan berpandu bioassai
dari sumber produk semulajadi.
Dua model Hypogen telah digunakan sebagai model sievers dalam pengskrinan maya
(ROC AUC =0.91 and 0.80; ݎ଻଴
ଶ = 0.92 and 0.90). Model ini telah disepadukan
dengan pendokan molekular untuk menyaring 3000 sebatian dari pangkalan data
NADI.
Keputusan penyaringan virtual telah menunjukkan bahawa sebatian zanton dari G.
mangostana (manggis) adalah hit utama diperolehi, menjadikan pokok ini terpilih
untuk selanjutnya dilakukan pemencilan sebatian.
Tujuh sebatian diperolehi daripada manggis memberikan perencatan lebih dari 80%
melalui kaedah pemencilan sebatian berpandukan bioassai. Potensi kesan perencatan
neuraminidase (NA) (C. perfringens-NA dan H1N1-NA) dalam kajian ini adalah
seperti berikut: garsinona D> -mangostin> -mangostin> garsinona C> 3-
isomangostin> gartanin> 8-deoksigartanin. Tujuh sebatian ini menunjukkan
pendokkan berkesan terhadap kawasan pengikat aktif NA.
Selepas itu, G. atroviridis dan G. celebica telah dipilih bagi mengukuhkan hipotesis
xix
bahawa Garcinia sp memberikan aktiviti rencatan neuraminidase. Asid garsinia dan
naringenin yang diperolehi dari buah dan daun G. atroviridis juga memberikan
perencatan neuraminidase tetapi kurang aktif berbanding G. mangostana.
Friedelina, katekin and dua terbitan lanastona (metil-3α, 23-dihidroksi-17,14-
friedolanstan-8,14,24-trien-26-oat dan 24E-3a,9,23-trihidroksi-17,14-friedolanostan-
14,24-dien-26-oat) telah diperolehi dari daun G. celebica melalui kaedah pemencilan
berpandukan bioassai. Katekin dan dua terbitan lanastona menunjukkan perencatan
yang kurang aktif, sedangkan friedelina tidak aktif.
Hanya lima sebatian (garsinona C, garsinona D, asid garcinia, naringenin, dan
katekin) menepati ciri-ciri “drug-like’ melalui kaedah peraturan lima. Sebatian yang
paling aktif didapati adalah garsinona D (IC50 = 6.7 μM)  
xx
COMPUTER-AIDED DRUG DESIGN OF POTENTIAL NEURAMINIDASE
INHIBITORS FROM PLANT EXTRACTS
ABSTRACT
Neuraminidase (NA) of influenza virus is responsible for the proliferation and
infections of the virus progeny, prompting several efforts to discover and optimize
new neuraminidase inhibitors. The main aim of this study is to discover new
potential neuraminidase inhibitor from the natural product source using computer-
aided (pharmacophore modelling-molecular docking) drug design method combined
with bioassay-guided isolation. Two Hypogen models were selected as screening
sievers (ROC AUC =0.91 and 0.80; ݎ଻଴
ଶ = 0.92 and 0.90). These models were
integrated with molecular docking to screen 3000 compounds from NADI database.
Virtual screening results showed that xanthone derivatives from G. mangostana
(mangosteen) were the top hits, thus provide rationale to select this plant for further
isolation. Seven compounds obtained from mangosteen showed inhibition more than
80 % by bioassay-guided isolation. The potency of neuraminidase (NA) (C.
perfringens-NA and H1N1-NA) inhibitory effect in this study is as follows:
garcinone D > -mangostin > -mangostin > garcinone C > 3-isomangostin >
gartanin > 8-deoxygartanin. These seven compounds were favourably docked to the
binding site of NA.
Subsequently, G. atroviridis and G. celebica were chosen to further prove the
hypothesis that Garcinia sp gave neuraminidase inhibition activity. Garcinia acid
and naringenin were obtained from G. atroviridis fruits and leaves and showed
potent against neuraminidase but less active compared to compounds from G.
xxi
mangostana.
Friedeline, catechin and two lanastone derivatives (methyl-3α, 23-dihydroxy-17,14-
friedolanstan-8,14,24-trien-26-oat and 24E-3a,9,23-trihydroxy-17,14-friedolanostan-
14,24-dien-26-oate) were obtained from G. celebica leaves by bioassay-guided
isolation method. Catechin and two lanastone derivatives were less active while
friedeline was inactive.
Only five compounds (garcinone C, garcinone D, garcinia acid, naringenin, and
catechin) fullfill as drug-like according to “rule of five”. The most active compound
of garcinone D showed the most potent activity against NA with IC50=6.70 µM.
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INTRODUCTION
1.1. Statement of the Problem
World Health Organisation (WHO) reported that influenza virus affected nearly 10-
20% of the world population, causing millions of people to be hospitalized and
resulted in a quarter to a half a million deaths per year (De Filette et al., 2005).
Influenza virus can be subdivided into three types A, B and C, but type C virus is less
pathogenic than A and B viruses. Avian and swine influenza are variants of type A
virus; with avian influenza represented the most pathogenic virus (Varghese, 1999,
Webster et al., 1997). Indonesia appeared to have the highest fatality rate caused by
avian flu in the world, with 160 deaths from 192 infected cases as of February 2013
(WHO, 2013). Cases of avian flu in China, Indonesia and several other Asian
countries in 2005 have led to awareness on the pandemic threat and prompted efforts
to control this disease. In June 2009, the swine flu outbreak (SIV) has alerted WHO
to classify it as a pandemic (level 6) (WHO, 2009) indicating widespread community
transmission. The pandemic was declared to be over in August 2010 and Malaysia
being also affected by this infection has reported 15,520 cases and 92 deaths up to
August 2010 (Bernama, 2010).
In general, influenza A virus consists of a membrane-enveloped, segmented,
negative-strand RNA with hemagglutinin (HA) and neuraminidase (NA) located on
the surface. HA and NA play a major role in viral replication. HA is responsible for
the attachment on the surface of the cell receptors that are connected with terminal
sialic acid (Colman, 1994), whereas NA is responsible for the proliferation and
2infections of the virus. In contrast to HA, NA has highly conserved amino acid
residues in its protein sequence. For this reason, the design of anti-influenza drug is
more attractive to the inhibition of NA. Existing NA inhibitors designed using
structure based drug design (SBDD) method such as oseltamivir (OTV) and
zanamivir (ZANA) are potent in treating influenza in human but suffer problem due
to resistance. Whereas peramivir (Sidwell and Smee, 2002) showed significantly
weak inhibition towards virus due to physiological effect (Bantia et al., 2006).
Therefore, the discovery of new active compounds that are potent against NA and
not susceptible to its resistances has become an important goal of drug discovery in
anti-influenza drug and this has also been the goal of this project.
To date, new NA inhibitors have been developed from synthetic chemicals, whereas
the use of bioactive compounds from natural product as starting materials is still
relevant. Synthesis of oseltamivir for example, utilise shikimic acid, which cannot be
obtained economically by synthesis but can be efficiently isolated from Chinese star
anise (Anderson, 2008). This project thus aims to leverage both Malaysia and
Indonesia’s rich natural resources to identify natural products that can be used as
drug components or the starting materials for drugs and drug products, especially in
the case of anti influenza drug.
1.2. Swine Influenza Virus (SIV)
In 1918, Spanish flu was first documented as a global pandemic that killed 50 million
people around the world with an estimated 550.000 people died in the US. Spanish
flu is an epizootic disease which has many clinical and pathologic similarities to
human influenza that appeared among pigs in the north-central, U.S. In 1930, Smith
3first reported that swine flu was caused by a virus. SIV belongs to the viral family of
Orthomyxoviridae of type A with H1N1 subtype. They are RNA viruses with a
segmented genome that comprise eight negative-sense, single-stranded RNA
segments (Webster et al., 1992). Two others pandemics appeared in 1957 and 1968
are known within the history of the 20th century (Webster et al., 1997). The viruses
that appeared in 1957 (Asian, H2N2) and 1968 (Hong Kong, H3N2) pandemics were
the products of gene reassortment between human and avian viruses, when avian
hemagglutinin and basic polymerase 1 (PB1) genes were brought to the human
population (Desenclos, 1996). There is evidence that the swine-origin inﬂuenza 
(H1N1) virus is more pathogenic than seasonal inﬂuenza A virus (Desenclos, 1996, 
Calore et al., 2011).
H1N1 influenza A virus was first detected in California USA in April 2009 and
subsequently referred to as swine-origin influenza A virus (Reid and Taubenberger,
2003b, Fanning et al., 2002). The virus was found in swine where H3 and N2, (HA
and NA, respectively) segments circulating concurrently in humans to replace the
avian-like H1N1 by reassortment (Castrucci et al., 1993, Claas et al., 1998, Reid and
Taubenberger, 2003a). This virus is not epidemic in pigs but is easily transmitted
between humans as found in Mexico (Fanning et al., 2002, Michaelis et al., 2009).
The arrangement of the genome into segments allows reassortment resulting a
diverse strains (Reid and Taubenberger, 2003b). The latest H1N1 is a descendent of
1918 pandemic strain which obtained new H2, N2, and PB1 genes through
reassortment with an avian influenza A virus (Kawaoka et al., 1989).
There are three types of SIV (H1N1, H2N2 and H3N2) found in pig and human
(Scholtissek, 1994). The cells of the swine respiratory tract contain
4sialyloligosaccharides receptor possessing both α-2,3-galactose and α-2,6-galactose 
of N-acetylneuraminic acid. α-2,3-galactose-N-acetylneuraminic acid is the favoured 
receptor for avian influenza viruses, whereas α-2,6-galactose-N-acetylneuraminic is 
the preferred receptor for mammalian influenza viruses (Ma et al., 2008, Scholtissek,
1994). This provides supportive evidence for the “mixing vessel” theory. In this
evolutionary process, swine might play an important role as a “mixing vessel” (Ma et
al., 2008), because swine are susceptible to infection with both avian and human
influenza viruses. Genetic reassortment between human and avian influenza viruses
occurs when these viruses co-infect an individual pig (Scholtissek, 1994, Scholtissek,
1990).
1.3. Avian Influenza Virus (AIV)
H5N1 avian influenza virus (AIV) is pathogenic for poultry and human (Liu et al.,
2005). Highly pathogenic avian influenza (HPAI) began distributing in Hong Kong
in 1997 (Subbarao et al., 1998). It circulated rapidly in Asia, Europe, and Africa
since 2003 and claimed at least 53 human lives (Asmara, 2006). In February 2007,
83 people reported to have been infected by avian influenza that led to the deaths of
63 people. WHO reported that the highest number of cases came from Egypt (29
cases), followed by Indonesia (9), Vietnam (7), China (2) and Cambodia (1) in 2010
(WHO, 2010b). Previously, these countries have also reported human cases of AIV
in 2009 (WHO, 2010a). In addition to the poultry, avian influenza virus could also
infect mammalian thus experts feared the possible emergence of a new subtype of
influenza virus that is able to transmit from human to human now that H5N1 virus is
proven to have been able to spread from birds to human.
5To date only viruses of H5 and H7 subtypes (and sometimes H9 subtype) have been
proven to cause HPAI. Amino acid composition of HA, NA, NS and PB2 proteins
contribute to the antigenic properties, virulence, and host specificity of the viruses
(Alexander, 2007). AIV has the ability to perform reassortment and genetic mutation
allowing the virus to change antigenic properties, pathogenicity, and host specificity.
One of the factors that play a role in AIV infection is the match between the viruses
with receptors on the surface of host cells. For the occurrence of infection, the AIV
binds to the cell surface glycoprotein and glycolipid containing sialyl-galactosyl
moieties [Neu5Ac(2-3 )Gal ] o r [Neu5Ac(2-6 )Gal ) ] . AIV isolated from
chickens binds with [Neu5Ac (2-3) Gal] while the human virus isolated has
specificity against with [Neu5Ac (2-6)-Gal] (Connor et al., 1994, Matrosovich et
al., 2000, Thompson et al., 2006, Matrosovich et al., 1992), thus AIV from chickens
could not easily infect to human (Matrosovich et al., 2004).
Research on the biomolecular aspect showed that in addition to sialic acid receptors
-2.6, which is the majority, human also has a network tracheobronchial ciliated
cells containing receptors with functional -2,6 bond-sialic acid and -2,3-sialic acid
in low proportion. -2,3 sialic acid receptors can be found on pneumosit in the lower
respiratory tract (Thompson et al., 2006). The existence of this receptor is probably
the main entry of avian viruses to human.
1.4. The Structure of Influenza Virus
Influenza virus belongs to the Orthomyxoviridae family. It is subdivided into
A, B, and C based on the antigenic differences of nucleoprotein (NP) and matrix
(M1) protein. Avian virus is the type A virus (Figure 1.1) and it causes epidemic and
pandemic in human and animals
antigens on its surface, hemaglutinin (HA, neuramindase (NA), and M protein. Both
HA and NA contained in total around 500 bumps covering envelope glycoprotein
lipid bilayer derived from the host.
subunits encoded in lipid
to the host cells on the surface that conjugated with glycoconjugate.
contains ketosidically
(Couceiro et al., 1993
merging the virus envelope with the host cell and is assisted by
enzyme (NA).
Figure 1.1. Structure of
of RNA. The virus contains three main antigens on its outside:
hemagglutinin, neuraminidase, and the M2 ion channel
2006).
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(Oxford, 2000). The virus contains three main
HA is a trimeric glycoprotein consists of three
membrane (Wagner et al., 2002). HA acts as the first access
-α-N-terminal connected to acetylneuraminic acid residue
). These glycoproteins contribute to the internalization
influenza A virus. The virus genome is made of 8 strands
Glycoconjugate
through
neuraminidase
(Romanova,
7Neuraminidase is an enzyme that prevents aggregation of the virions within the host
cell and facilitates the cell-to-cell spread by cleavage of glycosidic linkages to sialic
acid. The protein M1 controls the assembly of virion proteins and is situated in the
envelope lipid bilayer. The M2 protein which is an ion channel bridges the inside and
outside of the virus. In the viral envelope is a transcription complex required for viral
replication. It consists of RNA nucleoprotein (NP) and, polymerase PA, PB1, and
PB2 (Bardiya and Bae, 2005, Webster et al., 1992).
NA is a tetrameric glycoprotein which composed of four identical subunits (Colman
and Ward, 1985) and acts as a glycohydrolase that eradicates α-ketosidically at N-
terminal which is connected by acetylneuraminic acid residues from glycoconjugates
(Colman and Ward, 1985). Serologic and genetic analysis showed that virus avian
Influenza consists of 16 HA and 9 NA (WHO, 1980, Lee et al., 2005, Zhang et al.,
2009). N1 is currently the most common pathogenic NA in circulation. A detailed
structure of NA is explained below.
1.5. Neuraminidase (NA)
Neuraminidase (NA) is responsible in cleaving sialic acid in terminal receptors,
releasing new viruses from infected cells. NA is found particularly in diverse virus
families and bacteria, as well as in protozoa, some invertebrates and mammalian
(Schwerdtfeger and Melzig, 2010, Sander-Wewer et al., 1982). They have
differences in binding affinity or substrate preference, but they have conserved
domains and structural similarities (Schwerdtfeger and Melzig, 2010). NA plays a
vital role in influenza virus replication, and has a conserved active site residues thus
inhibition of NA can delay the release of virus progeny from infected cells. This will
8reduce the virus population and will give time for the immunity of the host cell in the
body to eliminate the virus (Garman and Laver, 2004). NA hydrolyze α-2,3-sialic 
acid from sugar (galactose), and is also involved in hydrolysis at α-2,6-sialic acid-
galactocyl, but this is less efficient especially if it is weak aglycon (sialic acid).
There are nine subtypes of neuraminidase from influenza A viruses (N1-N9) (Liu et
al., 1995). Type A influenza neuraminidases form two genetically distinct groups:
Group 1 consists of subtypes N1, N4, N5 and N8 while group-2 consists of N2, N3,
N6, N7 and N9. Group-1 has a 150-loop cavity adjacent to the active site that serves
as a gateway for the ligand to interact with NA (Russell et al., 2006). The cavity is
suitable for the active site in the development of new anti-influenza drugs (Rudrawar
et al., 2010).
1.6. The Active Site of Neuraminidase
The active site of NA has highly conserved active residues which are very specific to
the sialic acid as the natural ligand. NA active site contains 18 residues (6 basic, 7
acidic, 3 polar, and 2 hydrophobic) (Colman, 1994). Based on the chemical bonding
and interaction, NA active site can be divided into sub-pockets (Figure 1.2). Subsite
1 (S1) consists of triarginyl cluster (Arg118, Arg292, and Arg371), which has a
pocket of positive charge; thus it will interact with the carboxylic groups of the
ligand (Itzstein et al., 1996). S1 is called basic pocket which is important for
designing lead compound for NA inhibitors (Taylor, 2009). S2 subsite is negatively
charged and is composed of Glu 119 and Glu 227, and it interacts with the amine
group on the acetamido of sialic acid. S3 consists of Trp178 and Ileu222 and has
hydrophobic properties. The two residues are adjacent to Arg152 that binds to the
9water molecules. S4 consists of Ala246 and Arg224, which are adjacent to the
Ileu222 pocket and it is unoccupied by the functional groups of sialic acid (Stoll et
al., 2003). The pocket accommodates a methyl group from SA and Neu5Ac2en
(DANA) (Taylor, 2009). S4 is a new target for the development of new NA
inhibitors. S5 has a unique pocket with mixed polarity environment depending on the
incoming ligand. This site consists of carboxylate of Glu276 (trans-conformation)
and methyl of Ala 246. During enzymatic reaction, Glu276 and Glu277 form
hydrogen bonds with Tyr406 to stabilize the oxocarbonium ion with sialic acid.
Glu276 interacts with O8-O9 in glycerol (SA) (Taylor and Itzstein, 1994). In
addition to these amino acid residues, Asp151 has also an important role but not
defined on the S1-S5 sites. This carboxylic residue does not make direct contact
with DANA, but is believed to play an important role in catalysis by polarizing the
bond α-2,3-sialic acid-glycosidic. Asp115 with Glu119 and Glu227 are also involved 
in sialic acid hydrolysis through the involvement of water molecules (Taylor and
Itzstein, 1994).
Figure 1.2. The interaction of DANA inside a neuraminidase active site in (a) 2D
and (b) 3D representative (taken from PDB ID : 1NNB) (from Stoll et
al., 2003).
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The availability of three-dimensional of structure of NA has played an important role
in the discovery of new inhibitor of neuraminidase. Varghese et al. (1983)
determined the first three-dimensional of NA (N2 subtype structure) using X-ray
crystallography at 2.9 Å resolution (Varghese et al., 1983).They also solved the first
complex structure of NA-sialic acid in 1992 (PDB id; 2bat) (Varghese et al., 1992a).
To date, there have been many crystal structures of neuraminidase available in
Protein Data Bank (PDB). Of the 109 neuraminidase proteins (155 from viruses, 52
from bacteria, and 39 from eukaryota) stored in PDB, only 141 protein
neuraminidase were derived from influenza virus. They represent three subtypes of
neuraminidase and which12 neuraminidase belonging to N1 subtype were found as
shown in Table 1.1.
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Table 1.1. List of some influenza A of neuraminidase structures of influenza A
virus in Protein Data Bank (www.rscb.org).
PDB
code
sub-
type Strain Ligand
Resolution
[Å] Reference
3T16 N1 B/BEIJING/1/87 Apo 2.5 (Russell et al., 2006)
2HTY N1 B/BEIJING/1/87 Apo 2.5 (Russell et al., 2006)
2HUO N1 B/BEIJING/1/87 OTV 2.95 ibid
2HU4 N1 B/LEE/40 OTV 2.5 ibid
3BEQ N1 A/BrevigMission/1/1918 H1N1 Apo 1.64 (Xu et al., 2008)
3CYE N1 H1N1 1918 Apo 1.65 ibid
3B7E N1 A/BrevigMission/1/1918 OTV 1.45 ibid(Xu et al., 2008)
3CKZ N1 H5N1 ZANA 1.9 (Collins et al., 2008)
3CL0 N1 H5N1 OTV 2.2 ibid
3CL2 N1 H5N1 OTV 2.54 ibid
3NSS N1 A/California/04/2009/H1N1 Apo 1.9 (Li et al., 2010)
4B7J N1 H1N1 2009: Resistance I223R OTV 2.42 (van der Vries et al., 2012)
1ING N2 A/TOKYO/3/67 BANA51 2.4 (Singh et al., 1995)
1INH N2 A/TOKYO/3/67 BANA62 2.4 ibid
1INW N2 A/TOKYO/3/67 AXP3 2.4 ibid
1INX N2 A/TOKYO/3/67 EQP4 2.4 ibid
1IVC N2 A/TOKYO/3/67 BANA25 2.4 (Jedrzejas et al., 1995)
1IVD N2 A/TOKYO/3/67 BANA16 1.8 ibid
1IVE N2 A/TOKYO/3/67 BANA37 2.4 ibid
1IVF N2 A/TOKYO/3/67 DANA 2.4 ibid
2BAT N2 A/TOKYO/3/67 Sialic
acid
2 (Varghese et al., 1992b)
1NNB N9 A/TERN/AUSTRALIA/G70C/75 DANA 2.8 (Bossart-Whitaker et al.,
1993)
1NNC N9 A/TERN/AUSTRALIA/G70C/75 ZANA 1.8 ibid
1INY N9 A/TERN/AUSTRALIA/G70C/75 EQP 2.4 (White et al., 1995)
1MWE N9 A/TERN/AUSTRALIA/G70C/75 Sialic
acid
1.7 (Varghese et al., 1997)
2QWI N9 A/TERN/AUSTRALIA/G70C/75 G208 2 (Varghese et al., 1998)
2QWJ N9 A/TERN/AUSTRALIA/G70C/75 G289 2 ibid
2QWK N9 A/TERN/AUSTRALIA/G70C/7 G3910 1.8 ibid
1BJI N9 A/TERN/AUSTRALIA/G70C/75 DPC11 2 (Taylor et al., 1998)
1F8D N9 A/TERN/AUSTRALIA/G70C/75 9-amino-
DANA
1.4 (Smith et al., 2001)
1F8E N9 A/TERN/AUSTRALIA/G70C/75
4,9-
amino-
DANA
1.4 ibid
1BANA5; 4-(acetylamino)-3-[(hydroxyacetyl)amino]benzoic acid
2BANA6; 4-(acetylamino)-3-[(aminoacetyl)amino]benzoic acid
3AXP; 4-acetamido-2,4-didexoy-d-glycero-β-d- galacto-octopyranosylphosphonic acid (an axial phosphonate) 
4EQP; 4-acetamido-2,4-dideoxy-d-glycero--d-galacto-1-octopyranosyl)phosphonic acid
5BANA2; 4-(acetylamino)-5-amino-3-hydroxybenzoic acid
6BANA1; 4-(acetylamino)-5-amino-3-hydroxybenzoic acid
7BANA3; 4-(acetylamino)-3-amino benzoic acid
8G20; 4-acetyl-4-guanidino-6-methyl(propyl)carboxamide- 4,5-dihydro-2h-pyran-2-carboxylic acid
9G28; 5-n-acetyl-4-amino-6-diethylcarboxamide-4,5-dihydro-2h-pyran-2-carboxylic acid
10G39; (3R,4R,5S)-4-(acetylamino)-5-amino-3-(pentan- 3-yloxy)cyclohex-1-ene-1-carboxylic acid
11DPC; 5-acetylamino-4-amino-6-(phenethyl-propyl-carbamoyl)-5,6-dihydro-4h-pyran-2-carboxylic acid
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1.7. Computer-Aided Drug Design (CADD)
The use of computational techniques has been shown to further increase the
efficiency of drug discovery and development (Zhang, 2011, Marshall, 1987).
Computer-aided molecular design (CAMD) or in silico or computer-aided drug
design (CADD) is being applied to expedite and assist hit-to-lead selection, hit
identification, optimize the absorption, distribution, metabolism, excretion (ADME)
and profile toxicity (Kapetanovic, 2008).
CADD could be devided into; (1) ligand based design, (2) structure based design,
and (3) de novo design. There are various methods of ligand-based drug design
(LBDD) can be applied, if protein structures are unknown, such as this method
Quantitative Structure Activity Relationship (QSAR) and pharmacophore modelling
(Kapetanovic, 2008, Zhang, 2011). The knowledge of ligand such as
pharmacological effect and bioactivity is important in LBDD. A ligand set with
known activity can generate model by computational approach such as QSAR,
pharmacophore modelling, and database mining (Zhang, 2011). The retrieval of all
3D structures from a database considered as being similar to a given target structure
is comparable with 2D similarity searching. However, 3D similarity searching reduce
the problem of conformational flexibility (Terfloth and Gasteiger, 2003). The
successful stories of LBDD approaches in facilitating drug discovery have been
reported by Kubinyi (Kubinyi, 2006, Kubinyi, 1993).
In SBDD, structural knowledge obtained from ligand–protein complexes (X-ray
crystallography or NMR data) can primarily facilitate the design of focused
structure-based libraries by optimizing ligand–receptor complementary interactions,
in an effort to increase potency and specificity (Orry et al., 2006, Hubbard, 2010).
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The applications of SBDD include the discovery of potent and selective HIV
protease inhibitors (Rubin et al., 1978, Wlodawer and Vondrasek, 1998), thrombin
inhibitors (Wagner et al., 1998, Bohm et al., 1999), and neuraminidase inhibitors
(Itzstein et al., 1993). Recent example of this method, peramivir (BCX-1812) which
is developed using structure based method utilise the crystallography structure of a
highly conserved NA active site and its substrate interactions (Young et al., 2001,
Babu et al., 2000).
On the other hand, De novo method is practically used when the ligand is unknown,
with a known target. De novo ligand design will be able to test many structures in a
short period of time and arrange them into a ranked list based on an accurate
prediction of binding free energies since the latter reflects actual binding propensities
(DeWitte and Shakhnovich, 1996, Bohm, 1998, Hartenfeller and Schneider, 2010).
One of CADD tools, which is the most popular in the last 10 years is virtual
screening (Lengauer et al., 2004). Both LBDD and SBDD approaches are powerful
technologies, which can be applied to virtual screening (VS) for lead identification
and optimization (Zhang, 2011).
1.8. Neuraminidase as a Target for Drug Discovery using SBDD technique
As mentioned in Section 1.7, SBDD is a powerful technique in the process of
discovery and development of drug. SBDD approach is responsible for evaluating
the complementarities and predicting the possibility of binding modes and affinities
between ligands and their macromolecular receptors (Zhang, 2011). The availability
of X-ray crystal structures of the influenza virus NA with and without a ligand such
as α-Neu5Ac and Neu5Ac2en (Colman et al., 1983, Varghese et al., 1983, Varghese 
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et al., 1992a) provides the key in designing NA inhibitors. Edmond and co-workers
(Edmond et al., 1966) together with Meindle’s group (Meindl and Tuppy, 1969)
started a random screening method in drug discovery. This method is based on
guided activity that focused on trial and error, but the method did not work as the
compounds easily produced drug resistant. Goodford (Goodford, 1985) calculated
the interaction energy between ligand and the target by using computational method
and found that interaction of both ligand and target can be predicted by using
predictive software programs such as GRID (Goodford, 1985). The software
program GRID forms the collection of computing resourch that performs task from
multiple sites. The GRID programs has been used by von Itztein et al. (Itzstein et al.,
1996) to design NA inhibitors using SBDD approach. Energy interaction between
sialic acid (SA) and NA in the complex crystal structure becomes the basis for drug
design a NA inhibitors (Wade, 1997).
It is possible to design highly potent NA inhibitors with SBDD as has been reported
in the discovery of zanamivir (ZANA) (Taylor and Itzstein, 1994). Using GRID
(Goodford, 1984, Goodford, 1985), the active site of NA is explored for the ability to
accommodate a variety of groups such as carboxylates, amine, methyl and phosphate
functional groups to get a potent and effective inhibiting NA (Itzstein et al., 1996).
Several compounds have been successfully modified and optimized based on charge
and shape of the character of active sites through SBDD methods, such as ZANA
(Itzstein et al., 1996) and OTV (Kim et al., 1997). Based on the results of
computational chemistry, von Itztein et al. (Itzstein et al., 1996) replaced the
hydroxyl group at C-4 from the Neu5Ac2en with amine base groups into 4-amino-4-
deoxy-Neu5Ac2en (Figure 1.3(a)) and further replaced with a guanidino group
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(ZANA) (Figure 1.3(b)). Based on these data, C-4 group on the guanidino of ZANA
successfully interact with carboxylic groups on the site active residues (Glu119 and
Glu227) which leads to better inhibition of NA of Neu5Ac2en. The importance of
NA in the history of the pathogenesis of influenza virus infection and the properties
of the active side residue which is highly conserved lead to a concrete reason to
design of small molecule, which is selective and effective towards NA.
The glycerol moieties of ZANA interact with the active site of NA in a similar way
to DANA. The in silico results showed that the replacement of glycerol with a more
hydrophobic group makes the ligand more stable in solid form (oral administration),
whereas ZANA is stable only in the form of solution (intravenous). In addition,
QSAR studies explained that the replacement of glycerol with considerations chain
length, branches, and stereochemistry of alkyl groups also improve the inhibition
against NA. This is the basis in designing OTV (GS4071) (Figure 1.4(a)). Kim et al.
performed optimization by the replacement of glycerol with 3-pentyl ether but
maintaining acetamido and amino groups in the GS 4071(Kim et al., 1997). In this
discovery, GS4104 (Figure 1.4(b)) has been developed for the purpose of drug
formulations, which is the ester derivative of OTV (Lew et al., 2000, Lew et al.,
1999, Li et al., 1998).
(A) (B)
Figure 1.3. The structures of (a) 4-amino-4-deoxy-Neu5Ac2en and (b) zanamivir.
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Based on the success the discovery of ZANA (Itzstein et al., 1996) and OTV (Lew et
al., 2000), SBDD has played an important role in the discovery of NA inhibitors.
However, the constant threat of pandemic avian influenza (Monto, 2005) and the
emergence of strains resistant to OTV (Tamiflu) makes the development of new
effective NA inhibitor interesting for drug development research.
HOOC O
NHAc
NH2
EtOOC O
NHAc
NH2
(A) (B)
Figure 1.4. (A) oseltamivir carboxylate (GS 4071) (B) oseltamivir (GS 4104).
1.9. Pharmacophore Modelling
IUPAC defines pharamcophore as the ensemble of steric and electronic features,
which are required to ensure the optimal molecular interactions with a specific
biological target structure and to trigger its biological response (IUPAC, 2007).
As QSAR theory that was developed by Hansch and Fujita showed that the sum of
the steric, electronic, and hydrophobic effects of substituent’s in a compound
determines its biological activity, pharmacophoric patterns are also influenced by
streometry, steric (atoms are accessible to the receptor), and electrostatic (Kubinyi,
1993). Technique of building pharmacophore is based on generating conformational search
then mapping common groups in terms of a particular or specific atom type (e.g.
hydrogen bond donor or acceptor), functional groups or some other similar
properties. After that, the molecules are aligned and superimposed at the specified
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points in a defined mode and then pharmacophore is created by joining the sites in
common and calculating distances by averaging sites of superposition in a least-
squares fit calculation. Spatial relationships between the pharmacophoric groups and
relationships can be expressed as distances, angles, and torsions. The 3D (distances,
angles, and torsions) pharmacophore features may describe the properties of the
geometric points as to the type of interaction with the receptor (Langer et al., 2007).
Typically, pharmacophore features include hydrogen bond donor, hydrogen bond
acceptor, aromatic, hydrophobic, positive ionizable, and negative ionizable. In
comparing a ligand and a pharmacophore, the quality of the mapping were indicated
by the fit value, a higher fit value represents a better fit.
1.9.1. Pharmocophore Software Tools
Gund et al. (Gund, 2000) developed the first pharmacophore software derived by
using 3D database, but at that time (around 1974) only a few 3D databases available.
The availability of 3D databases significantly increased the benefits to reach
electronic pharmacophore models that could predict bioactivity. DISCO was the first
pharmacophore software which incorporated 3D-searching in 1990 (Martin, 1995).
GASP (Genetic Algorithm Superposition Program) was created for pharmacophore
identification by Jones et al. (Jones et al., 1995). CATALYST was recently one of
the most popular pharmacophore modelling. CATALYST algorithms utilized to
generating pharmacophore hypothesis include HipHop, HipHoprefine, Hypogen, and
Hyporefine (Poptodorov et al., 2005, Clement and Mehl, 2000).
HipHop algorithm is able to identify 3D-conformation of chemical features common
to a set of molecules (Barnum et al., 1996). There are three steps to generate feature-
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based 3D-pharamcophore aligment: (a) Generation of conformational model for each
molecules in the training set is generated, (b) Evaluating of each conformer is
evaluated for the presence of chemical feature, (c) Determination of 3D-
configuration of chemical features to input molecule is determined (Clement and
Mehl, 2000). Beside HipHop module, CATALYST also includes Hypogen
pharmacophore generation algorithm that is a ligand-based QSAR tool using
pharmacophoric overlap to predict activity (Li et al., 2000).
1.9.2. Basic Principle of Hypogen Algorithm
HipHop as mentioned above is a qualitative model that could not predict activity.
However, it is also the aim of CATALYST pharmacophore modelling to generate
quantitative model based on a set of compounds with biological activities to predict
the activity (Chaudhaery et al., 2010) and it is called Hypogen. Hypogen correlates
fit value with activity, thus the model generated can estimate the activity.
Information of ligands of activities such as IC50 or Ki is used to construct hypotheses
model that best correlates the activities between the estimated and that determined in
experiment of assay (Li et al., 2000).
There are three phases in Hypogen: constructive, subtractive, and optimization phase.
The first phase (constructive) is very similar to HipHop algorithm processing and
uses a pruned exhaustive search of all the conformations (Poptodorov et al., 2005,
Kurogi and Guner, 2001).
Hypogen identifies common configurations of features among discrete
conformations of a set of molecules (Barnum et al., 1996). The training set is divided
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into three categories; most active, moderate active and inactive. The most active
ligands can be calculated by the equation in below:
MA * UncMA — (A/ UncA) > 0.0……………….Equation 1.1
Where MA is the activity of the most active compound, UncMA is the
uncertainty in the measured activity and A is the activity of the active compound. Unc is
the uncertainty of the compounds and the value of an ‘‘Uncertainty’’ is 3 by default
(Kurogi and Guner, 2001, Guner et al., 2004). Compounds are considered inactive
when their activity is located at 3.5 logarithmic units below that of the most active
compound.
Constructive phase limits to the maximum of eight (Li et al., 2000). HypoGen
creates all acceptable pharmacophores containing up to five features among the two
most active compounds. The two most active in the list an investigated to identify
systematically by overlaying all their conformation, and only hypothesis that fit a
minimum subset of features of the rest a active compounds are maintained
(Poptodorov et al., 2005).
Subtractive phase will process programme to examine the hypothesis that were
created in the constructive phase and deleted pharmacophores from the data structure
that are not likely to be useful or hypotheses that ﬁt inactive training compounds 
(Taha et al., 2010, Poptodorov et al., 2005, Li et al., 2000).
A particular training compound is considered as being inactive if the activity of the
compound was 3.5 fold less than that of the most active compounds as following this
equation:
log (A) — log (MA) > 3.5………………. Equation 1.2
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where A and MA are the activity of the compound in the query and the activity of the
most active compound, respectively.
In optimization phase, simulated annealing algorithm is employed to apply the
predictive power of the hypotheses. Improving the score can be attempted by
applying small perturbation in the algorithm to the pharmacophores created (Li et
al., 2000). In the last step of optimization phase, quantitative extension of Occam's
razor selects the simplest models to estimate the activity correctly (Kurogi and Guner,
2001, Li et al., 2000).
1.9.3. Cost function in Hypogen
Hypogen generates the best hypothesis by using Cost function. Cost function in
Hypogen is used as the first step for validation process. Cost function is used to
evaluate the power of activity data of a compound as an input parameter and dataset.
CATALYST will generates two cost hypotheses (blank without activity data and
dataset with activity) to show the significance of the results (Poptodorov et al.,
2005). Fixed cost and null cost as theoretical costs are calculated in Hypogen as
output for correlation data between biological data reference and prediction (Sutter et
al., 2000). The value of weight cost is derived from gaussian form and the value
increases as the feature deviates from an ideal (2.0). Root mean squares (rms)
differences between the estimated and measured experiment activity for the data set
molecules is calculated as error component value. The configuration component is
called as constant cost. This value depends on the complexity of the hypothesis space
being optimized and equal to the entropy of the hypothesis space. The configuration
should not be greater than 17.0 in standard HypoGen mode.
21
1.10. Molecular Docking Simulation
Molecular docking is a key tool that combines computational and structural
molecular biology to predict the predominant binding mode(s) of a ligand with a
protein of known three-dimensional structure (Morris and Lim-Wilby, 2008). The
general schematic of molecular docking is illustrated in Figure 1.5 (Morris and Lim-
Wilby, 2008). The macromolecule as target and ligand must be first chosen based on
the disease type and then the structure selected has to be prepared in correspondence
with the needs of the docking method being employed. Finally, the results must be
analyzed based on ranking of scoring function. Binding area consists of its position
(x-, y-, and z-translations), orientation (Euler angles, axis-angle, or a quaternion),
and, if the ligand is flexible, its conformation is defined by the torsion angles for
each rotatable bond (Morris and Lim-Wilby, 2008).
Figure 1.5. Schematic chart of a protocol for docking simulation (Morris and Lim-
Wilby, 2008).
Target Selection
Target Preparation
Docking
Ligand Selection
Ligand Preparation
Evaluating Docking
Results
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There are two terms to understand how well this method performs. The terms are
matching and scoring, and this will explain how to determine successful docking
between ligand and macromolecule (protein) (Kroemer, 2003, Rarey et al., 1999).
Matching is a computational method to find optimum suitability between ligand and
protein based on sterical factor evaluation and its electrostatic contribution which
play a role in receptor-ligand interaction (Kroemer, 2003, Halperin et al., 2002),
while scoring function is used to distinguish correct or wrong solution and sort the
correct solution (Halperin et al., 2002).
It is a common concept for docking and fragments placement algorithms in
computer-aided drug design (Rarey et al., 1999). The chemical matching algorithm
generally ranks known inhibitors better than does matching based on shape (Shoichet
and Kuntz, 1993). Matching methods is introduced with different treatment of ligand,
conformational exploration, interaction ligand-protein representation, and prediction
of binding affinity.
Algorithms approach was developed by considering ligand as flexible molecule
(Moustakas et al., 2006, Rarey et al., 1999, Shoichet and Kuntz, 1993). Autodock
algorithm used in this study is based on the concepts of natural selection, genetic
algorithms, operated by creating a set of proposed solutions (‘population’) to a
problem of interest, evaluating them (‘fitness pressure’), and then using the best
solutions to develop a new set of proposed solutions (‘breeding’) (Douguet et al.,
2000), (Pegg et al., 2001, Zabinsky, 2009).
In Autodock, local search technique is embedded with GA which transforms
genotypic representations into phenotypic and is called Lamarckian Genetic
Algorithm (LGA) that enhanced performance relative to simulated annealing and GA
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alone. Three new search methods in Autodock 3 include a genetic algorithm; local
search method; and adaptive global-local search method based on Lamarckian
genetic algorithm.
Autodock uses semiempirical free energy force field to evaluate conformation during
docking simulation. The force field is parameterized using ligand-protein complexes
with known inhibition constant (Ki) (Morris et al., 2009).
Figure 1.6 describes how Autodock calculate the binding free energy. Ligand and
protein initially present as unbound conformation states. In the first step,
intramolecular energy is calculated from unbound conformation state of ligand that
binds to protein. In the second step, force field evaluates ligand to protein
intermolecular energy (in bound conformation) (Morris et al., 2009).
Figure 1.6. Illustration of calculation step of energy in autodock (Morris, et al.,
2009).
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In Autodock, the equation to calculate free energy of binding also calculates entropic
terms to the molecular mechanics, Equations 1.3 (Morris et al., 1998, Budin et al.,
2001).
G = Gvdw+ GHBOND + Gelec + Gconform + Gtor + Gsol.......... Equation 1.3
The above four terms are the typical molecular mechanics for hydrogen bonding,
dispersion or repulsion, electrostatics, and deviations from covalent geometry,
respectively; Gtor are the restriction of internal rotors, global rotation and
translation; and Gsol is desolvation upon binding and the solvent hydrophobic
effect wherein the entropy changes the interfaces between solute-solvent.
Autodock 3 software consists of three programs; AutoTors, AutoGrid, and AutoDock
(Goodsell and Olson, 1990). AutoTors assists the input of ligand coordinates thus the
ligand has flexibility with rotatable torsion angles and partial charge. AutoGrid
facilitates to pre-calculate a three-dimensional grid of interaction energy based on
macromolecular coordinates. It constructs three-dimensional grid surrounding the
coordinates for the protein target. Finally, AutoDock performs docking simulation
between ligand into macromolecules (Goodsell et al., 1996). In this step, the ligand
explores six spatial degrees of freedom of rotation-translation and an arbitrary
number of torsional degrees of freedom (Morris et al., 2008).
1.11. Ligand-Based Drug Design: Discovery of Neuraminidase Inhibitors
In recent time, sialic acid or Neu5Ac2en derivatives have been synthesized and
evaluated for their influenza virus sialidase inhibitory potential. There at least 268
compounds of Neu5Ac2en derivatives have been synthesized worldwide
(www.bindingDB.org) (Chen et al., 2002, Liu et al., 2007). In addition, molecular
